VMD
Viemed Healthcare, Inc.7.26
-0.11-1.49%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Maternal scaling details emerge
Q&A spotlighted maternal health scaling post-Lehan, with payers topping priorities ahead of cross-training sleep reps on OB-GYNs and bolstering back-office support—management bets it'll grow fastest. Margins stay stable via SG&A tech efficiencies and labor cuts to offset mix shift. Guidance assumes cautious vent growth amid NCD but aggressive sleep and full-year maternal ramps. RT headcount tracks patient volumes, with sequential dip tied to established markets. No major contradictions; answers reinforced prepared optimism. Payers unlock expansion. Investors eye maternal traction and vent cadence recovery.
Key Stats
Market Cap
281.58MP/E (TTM)
21.35Basic EPS (TTM)
0.34Dividend Yield
0%Recent Filings
8-K
10-K
FY2025 results
Viemed Healthcare crushed FY2025 ended December 31, 2025 with revenue jumping 20.5% y/y to $270.3M, fueled by Q4's $76.2M blockbuster—up 25.5% y/y and 6% q/q from Q3's $71.9M. Ventilator rentals (51% of revenue) grew 9.8% annually to $136.7M while equipment/supply sales exploded 62.7% to $50.3M on sleep resupply and Lehan Drugs acquisition; gross margins slipped to 57.5% from revenue mix shift. Q4 accelerated across vents (12,259 patients, +4% q/q), PAP therapy (34,528 patients, +8% q/q), and resupply. Operating cash flow hit $51.9M; $12.9M term debt funds growth. New share repurchase authorized. Yet CMS ventilator NCD changes risk reimbursement cuts.
8-K
Record results, buyback authorized
Viemed reported record 2025 results with $270.3M revenue, up 21%, $14.9M net income, up 33%, and $28.1M free cash flow, more than doubled from 2024, fueled by 62% PAP patient growth yet modest 4% ventilator rise. Board approved repurchasing up to 1,930,131 shares through March 2027. Cash flows durable. Guides $310M-$320M revenue, $65M-$69M Adjusted EBITDA for 2026.
8-K
Extended DDTL to 2026
10-Q
Q3 FY2025 results
Viemed Healthcare drove Q3 revenue to $71.9M, up 24% y/y from $58.0M, fueled by 86% surge in equipment/supply sales and 10% ventilator rental growth, though gross margin slipped to 57.5% from 59.3% on mix shift. Operating income held steady at $5.6M while diluted EPS edged to $0.09 from $0.10, reconciling to 40.5M shares. Closed Lehan Drugs in July 2025 for $28.7M (cash/contingent), recognizing $25.5M goodwill; cash fell to $11.1M after $26.3M outlay, with $21.1M under 2022 facilities (in covenant compliance). Operating cash flow hit $33.5M YTD. New CMS ventilator NCD poses reimbursement risk.
AHCO
AdaptHealth Corp.
10.35+0.08
ELMD
Electromed, Inc.
29.88+0.28
IRMD
iRadimed Corporation
96.87-0.15
IRME
IR-Med Inc.
0.02-0.01
LIVN
LivaNova PLC
63.08+0.02
MDT
Medtronic plc.
97.72-0.85
QIPT
Quipt Home Medical Corp.
3.52+0.02
RMD
ResMed Inc.
247.34-5.73
RMSL
RemSleep Holdings, Inc.
0.00+0.00
VVOS
Vivos Therapeutics, Inc.
2.02+0.00